Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sbio and Onyx Pharmaceuticals have expanded their development collaboration and option and license commercialisation agreement for Sbio's new JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively.
Subscribe to our email newsletter
The expanded agreement builds upon the development and commercialisation collaboration between the two companies announced in January 2009.
Onyx Pharmaceuticals is expected to provide $20m in funding to broaden and accelerate the existing development program for both compounds. The program will be expanded to include new indications for hematologic malignancies and myeloproliferative disorders.
However, Sbio will continue to perform the clinical development of SB1518 (ONX 0803) and preclinical through clinical development of SB1578 (ONX 0805).
Onyx Pharmaceuticals can elect to exercise its exclusive options for SB1518 (ONX 0803) and SB1578 (ONX 0805) separately and independently at certain predetermined stages of development for each compound in all indications in the US, Canada and Europe. Sbio would retain rights to develop and commercialise SB1518 and SB1578 in the rest of the world.
Jan-Anders Karlsson, CEO of Sbio, said: “We have made significant progress in the development of our novel JAK2 inhibitors and the new funding by Onyx further validates the strength of our collaboration and underscores the success of our joint programs. Advancing SB1518 and SB1578 into new indications will generate greater value in our assets and is expected to expedite future commercialisation.”
Anthony Coles, president and CEO of Onyx Pharmaceuticals, said: “We believe these JAK2 inhibitors have potential as important cancer therapeutics, and it is to the advantage of patients affected by these diseases to accelerate and broaden their clinical testing into multiple hematologic and myeloproliferative disorders.
“Expanding our collaboration with Sbio on these programs fits with Onyx Pharmaceuticals’ vision to invest in novel therapies and strengthens our position as an emerging oncology leader.”